Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Nebenwirkungen · Ozempic
Ozempic 0.25 mg solution for injection in pre-filled pen Ozempic 0.5 mg solution for injection in pre-filled pen Ozempic 1 mg solution for injection in pre-filled pen Ozempic 2 mg solution for injection in pre-filled pen Ozempic 0.25 mg solution for injection in pre-filled syringe Ozempic 0.5 mg solution for injection in pre-filled syringe Ozempic 1 mg solution for injection in pre-filled syringe · Abschnitt 4.8 · PDF-Seite 8
HOS-135980 · Präparat HOS-097800
Decreased
appetite
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-25T12:02:00Z · SHA-256 57219aa6be0c50a4f2cc98001152ec6dcce36b4e4c6ae43650c37f58899b3d2c · Passage 93a8c3d2071302e877a468169b8b1712506bed35293faa6301e8f39e5175ed6d · Zeichen 2151–2207 im Abschnitt
Nebenwirkungen · Ozempic
Ozempic 0.25 mg solution for injection in pre-filled pen Ozempic 0.5 mg solution for injection in pre-filled pen Ozempic 1 mg solution for injection in pre-filled pen Ozempic 2 mg solution for injection in pre-filled pen Ozempic 0.25 mg solution for injection in pre-filled syringe Ozempic 0.5 mg solution for injection in pre-filled syringe Ozempic 1 mg solution for injection in pre-filled syringe · Abschnitt 4.8 · PDF-Seite 8
HOS-135981 · Präparat HOS-097800
Nervous Dizziness Dysgeusia Dysaesthes
system Headache iad
disorders
Eye disorders Diabetic Non-
retinopathy arteritic
complicati anterior
onsb ischaemic
optic
neuropathy
(NAION)
Cardiac Increased
disorders heart rate
Gastrointesti- Nausea Vomiting Acute Intestinal
nal disorders Diarrhoea Abdominal pancreatitis obstruction
d
pain Delayed
Abdominal gastric
distension emptying
Constipatio
n
Dyspepsia
Gastritis
Gastro-
oesophage
al
reflux
disease
Eructation
Flatulence
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-25T12:02:00Z · SHA-256 57219aa6be0c50a4f2cc98001152ec6dcce36b4e4c6ae43650c37f58899b3d2c · Passage 76677b24bca059e0e17905647a2d38b35928f4e4ff52198c2c64704835c5010c · Zeichen 2210–4191 im Abschnitt
Nebenwirkungen · Ozempic
Ozempic 0.25 mg solution for injection in pre-filled pen Ozempic 0.5 mg solution for injection in pre-filled pen Ozempic 1 mg solution for injection in pre-filled pen Ozempic 2 mg solution for injection in pre-filled pen Ozempic 0.25 mg solution for injection in pre-filled syringe Ozempic 0.5 mg solution for injection in pre-filled syringe Ozempic 1 mg solution for injection in pre-filled syringe · Abschnitt 4.8 · PDF-Seite 8–9
HOS-135982 · Präparat HOS-097800
8
MedDRA Very common Common Uncommon Rare Very Rare Not known
system organ
class
Hepatobiliary Cholelithia
disorders sis
Skin and Angioedem
subcutaneous ad
tissue
disorders
General Fatigue Injection
disorders and site
administra- reactions
tion site
conditions
Investigations Increased
lipase
Increased
amylase
Weight
decreased
a)
Hypoglycaemia defined as severe (requiring the assistance of another person) or symptomatic in combination
with a blood glucose <3.1 mmol/L.
b)
Diabetic retinopathy complications is a composite of: retinal photocoagulation, treatment with intravitreal
agents, vitreous haemorrhage, diabetes-related blindness (uncommon). Frequency based on cardiovascular
outcomes trial.
c)
Grouped term covering also adverse events related to hypersensitivity such as rash and urticaria.
d)
From post-marketing reports.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-25T12:02:00Z · SHA-256 57219aa6be0c50a4f2cc98001152ec6dcce36b4e4c6ae43650c37f58899b3d2c · Passage 5a9662bc964a53072f0c8139f1f3ada2034952886733e63ec07a423deea00f0f · Zeichen 4246–5734 im Abschnitt
Nebenwirkungen · Ozempic
Ozempic 0.25 mg solution for injection in pre-filled pen Ozempic 0.5 mg solution for injection in pre-filled pen Ozempic 1 mg solution for injection in pre-filled pen Ozempic 2 mg solution for injection in pre-filled pen Ozempic 0.25 mg solution for injection in pre-filled syringe Ozempic 0.5 mg solution for injection in pre-filled syringe Ozempic 1 mg solution for injection in pre-filled syringe · Abschnitt 4.8 · PDF-Seite 9
HOS-135983 · Präparat HOS-097800
2-year cardiovascular outcomes and safety trial
In cardiovascular high risk population the adverse reaction profile was similar to that seen in the other
phase 3a trials (described in section 5.1).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-25T12:02:00Z · SHA-256 57219aa6be0c50a4f2cc98001152ec6dcce36b4e4c6ae43650c37f58899b3d2c · Passage e5ab8affea78f0eae524d693184aa0eb9b4361ba58acfc7ee5a11e1354bac1b4 · Zeichen 5736–5933 im Abschnitt
Nebenwirkungen · Ozempic
Ozempic 0.25 mg solution for injection in pre-filled pen Ozempic 0.5 mg solution for injection in pre-filled pen Ozempic 1 mg solution for injection in pre-filled pen Ozempic 2 mg solution for injection in pre-filled pen Ozempic 0.25 mg solution for injection in pre-filled syringe Ozempic 0.5 mg solution for injection in pre-filled syringe Ozempic 1 mg solution for injection in pre-filled syringe · Abschnitt 4.8 · PDF-Seite 9
HOS-135984 · Präparat HOS-097800
Description of selected adverse reactions
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-25T12:02:00Z · SHA-256 57219aa6be0c50a4f2cc98001152ec6dcce36b4e4c6ae43650c37f58899b3d2c · Passage f66db2a8100a521c1dea72ff90e696fa3846f9d5fcd6cf8e5e03ce5d71bde4a7 · Zeichen 5935–5976 im Abschnitt
Nebenwirkungen · Ozempic
Ozempic 0.25 mg solution for injection in pre-filled pen Ozempic 0.5 mg solution for injection in pre-filled pen Ozempic 1 mg solution for injection in pre-filled pen Ozempic 2 mg solution for injection in pre-filled pen Ozempic 0.25 mg solution for injection in pre-filled syringe Ozempic 0.5 mg solution for injection in pre-filled syringe Ozempic 1 mg solution for injection in pre-filled syringe · Abschnitt 4.8 · PDF-Seite 9
HOS-135985 · Präparat HOS-097800
Hypoglycaemia
No episodes of severe hypoglycaemia were observed when semaglutide was used as monotherapy.
Severe hypoglycaemia was primarily observed when semaglutide was used with a sulfonylurea (1.2%
of subjects, 0.03 events/patient year) or insulin (1.5% of subjects, 0.02 events/patient year). Few
episodes (0.1% of subjects, 0.001 events/patient year) were observed with semaglutide in combination
with oral antidiabetics other than sulfonylureas.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-25T12:02:00Z · SHA-256 57219aa6be0c50a4f2cc98001152ec6dcce36b4e4c6ae43650c37f58899b3d2c · Passage b2394c95fedcba27aeb9bd2b91586b466ec18b1fc84c07d939d4b1960af1b563 · Zeichen 5978–6430 im Abschnitt
Nebenwirkungen · Ozempic
Ozempic 0.25 mg solution for injection in pre-filled pen Ozempic 0.5 mg solution for injection in pre-filled pen Ozempic 1 mg solution for injection in pre-filled pen Ozempic 2 mg solution for injection in pre-filled pen Ozempic 0.25 mg solution for injection in pre-filled syringe Ozempic 0.5 mg solution for injection in pre-filled syringe Ozempic 1 mg solution for injection in pre-filled syringe · Abschnitt 4.8 · PDF-Seite 9
HOS-135986 · Präparat HOS-097800
American Diabetes Association (ADA) classified hypoglycaemia occurred in 11.3%
(0.3 events/patient year) of patients when semaglutide 1 mg was added to SGLT2 inhibitor in
SUSTAIN 9 compared to 2.0% (0.04 events/patient year) of placebo-treated patients. Severe
hypoglycaemia was reported in 0.7% (0.01 events/patient year) and 0% of patients, respectively.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-25T12:02:00Z · SHA-256 57219aa6be0c50a4f2cc98001152ec6dcce36b4e4c6ae43650c37f58899b3d2c · Passage 7334e1040400c6f7faf532049c04a1b169e238d37c9dc4ef235af27c6389dd17 · Zeichen 6432–6788 im Abschnitt
Nebenwirkungen · Ozempic
Ozempic 0.25 mg solution for injection in pre-filled pen Ozempic 0.5 mg solution for injection in pre-filled pen Ozempic 1 mg solution for injection in pre-filled pen Ozempic 2 mg solution for injection in pre-filled pen Ozempic 0.25 mg solution for injection in pre-filled syringe Ozempic 0.5 mg solution for injection in pre-filled syringe Ozempic 1 mg solution for injection in pre-filled syringe · Abschnitt 4.8 · PDF-Seite 9
HOS-135987 · Präparat HOS-097800
In a 40-week phase 3b trial in patients receiving semaglutide 1 mg and 2 mg, the majority of the
hypoglycaemic episodes (45 out of 49 episodes) occurred when semaglutide was used in combination
with sulfonylurea or insulin. Overall, there was no increased risk of hypoglycaemia with semaglutide
2 mg.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-25T12:02:00Z · SHA-256 57219aa6be0c50a4f2cc98001152ec6dcce36b4e4c6ae43650c37f58899b3d2c · Passage 3aa9a6df675fb1b24ddc473d1fdf5132f586d2e3e283bc89c32cb248feb82cf6 · Zeichen 6790–7090 im Abschnitt
Nebenwirkungen · Ozempic
Ozempic 0.25 mg solution for injection in pre-filled pen Ozempic 0.5 mg solution for injection in pre-filled pen Ozempic 1 mg solution for injection in pre-filled pen Ozempic 2 mg solution for injection in pre-filled pen Ozempic 0.25 mg solution for injection in pre-filled syringe Ozempic 0.5 mg solution for injection in pre-filled syringe Ozempic 1 mg solution for injection in pre-filled syringe · Abschnitt 4.8 · PDF-Seite 9
HOS-135988 · Präparat HOS-097800
Gastrointestinal adverse reactions
Nausea occurred in 17% and 19.9% of patients when treated with semaglutide 0.5 mg and 1 mg,
respectively, diarrhoea in 12.2% and 13.3% and vomiting in 6.4% and 8.4%. Most events were mild to
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-25T12:02:00Z · SHA-256 57219aa6be0c50a4f2cc98001152ec6dcce36b4e4c6ae43650c37f58899b3d2c · Passage de4eddab93aee0396058eedd18d4220ee0bad96f6c5259874e55aa29c8de8d3a · Zeichen 7092–7317 im Abschnitt
Nebenwirkungen · Ozempic
Ozempic 0.25 mg solution for injection in pre-filled pen Ozempic 0.5 mg solution for injection in pre-filled pen Ozempic 1 mg solution for injection in pre-filled pen Ozempic 2 mg solution for injection in pre-filled pen Ozempic 0.25 mg solution for injection in pre-filled syringe Ozempic 0.5 mg solution for injection in pre-filled syringe Ozempic 1 mg solution for injection in pre-filled syringe · Abschnitt 4.8 · PDF-Seite 9–10
HOS-135989 · Präparat HOS-097800
9
moderate in severity and of short duration. The events led to treatment discontinuation in 3.9% and 5%
of patients. The events were most frequently reported during the first months on treatment.
Patients with low body weight may experience more gastrointestinal side effects when treated with
semaglutide.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-25T12:02:00Z · SHA-256 57219aa6be0c50a4f2cc98001152ec6dcce36b4e4c6ae43650c37f58899b3d2c · Passage 35a7f74411283c95cc6f9426bb2a5d93dc080d8803d9ea0e0493d6dedb78d95f · Zeichen 7376–7684 im Abschnitt
Nebenwirkungen · Ozempic
Ozempic 0.25 mg solution for injection in pre-filled pen Ozempic 0.5 mg solution for injection in pre-filled pen Ozempic 1 mg solution for injection in pre-filled pen Ozempic 2 mg solution for injection in pre-filled pen Ozempic 0.25 mg solution for injection in pre-filled syringe Ozempic 0.5 mg solution for injection in pre-filled syringe Ozempic 1 mg solution for injection in pre-filled syringe · Abschnitt 4.8 · PDF-Seite 10
HOS-135990 · Präparat HOS-097800
In a 40-week phase 3b trial in patients receiving semaglutide 1 mg and 2 mg, nausea occurred in
similar proportions of patients when treated with semaglutide 1 mg and 2 mg, respectively. Diarrhoea
and vomiting occurred in higher proportions of patients when treated with semaglutide 2 mg compared
to semaglutide 1 mg. The gastrointestinal adverse reactions led to treatment discontinuation in similar
proportions in the semaglutide 1 mg and 2 mg treatment groups.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-25T12:02:00Z · SHA-256 57219aa6be0c50a4f2cc98001152ec6dcce36b4e4c6ae43650c37f58899b3d2c · Passage fb4ef281daf9a5549563beaf8eac97270b2e20c99a731381d7d8061769d5660a · Zeichen 7686–8149 im Abschnitt
Nebenwirkungen · Ozempic
Ozempic 0.25 mg solution for injection in pre-filled pen Ozempic 0.5 mg solution for injection in pre-filled pen Ozempic 1 mg solution for injection in pre-filled pen Ozempic 2 mg solution for injection in pre-filled pen Ozempic 0.25 mg solution for injection in pre-filled syringe Ozempic 0.5 mg solution for injection in pre-filled syringe Ozempic 1 mg solution for injection in pre-filled syringe · Abschnitt 4.8 · PDF-Seite 10
HOS-135991 · Präparat HOS-097800
In concomitant use with an SGLT2 inhibitor in SUSTAIN 9, constipation and gastro-oesophageal
reflux disease occurred in 6.7% and 4% respectively of patients treated with semaglutide 1 mg
compared to no events for placebo-treated patients. The prevalence of these events did not decrease
over time.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-25T12:02:00Z · SHA-256 57219aa6be0c50a4f2cc98001152ec6dcce36b4e4c6ae43650c37f58899b3d2c · Passage 66b46a4ac5a26a72e6b93cb960be425ce4a2e1e0af8ae9c26b4cc4fa2d24f73b · Zeichen 8151–8448 im Abschnitt
Nebenwirkungen · Ozempic
Ozempic 0.25 mg solution for injection in pre-filled pen Ozempic 0.5 mg solution for injection in pre-filled pen Ozempic 1 mg solution for injection in pre-filled pen Ozempic 2 mg solution for injection in pre-filled pen Ozempic 0.25 mg solution for injection in pre-filled syringe Ozempic 0.5 mg solution for injection in pre-filled syringe Ozempic 1 mg solution for injection in pre-filled syringe · Abschnitt 4.8 · PDF-Seite 10
HOS-135992 · Präparat HOS-097800
Patients with gastroparesis may experience more serious or severe gastrointestinal effects when treated
with semaglutide.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-25T12:02:00Z · SHA-256 57219aa6be0c50a4f2cc98001152ec6dcce36b4e4c6ae43650c37f58899b3d2c · Passage 826dc93e8dde19221fd21b1296906465a112e7a2218fe9152387dd3703a8be63 · Zeichen 8450–8571 im Abschnitt
Nebenwirkungen · Ozempic
Ozempic 0.25 mg solution for injection in pre-filled pen Ozempic 0.5 mg solution for injection in pre-filled pen Ozempic 1 mg solution for injection in pre-filled pen Ozempic 2 mg solution for injection in pre-filled pen Ozempic 0.25 mg solution for injection in pre-filled syringe Ozempic 0.5 mg solution for injection in pre-filled syringe Ozempic 1 mg solution for injection in pre-filled syringe · Abschnitt 4.8 · PDF-Seite 10
HOS-135993 · Präparat HOS-097800
Acute pancreatitis
The frequency of adjudication-confirmed acute pancreatitis reported in phase 3a clinical trials was
0.3% for semaglutide and 0.2% for the comparator, respectively. In the 2-year cardiovascular
outcomes trial the frequency of acute pancreatitis confirmed by adjudication was 0.5% for semaglutide
and 0.6% for placebo (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-25T12:02:00Z · SHA-256 57219aa6be0c50a4f2cc98001152ec6dcce36b4e4c6ae43650c37f58899b3d2c · Passage 586a30135fac8f985b71805b5d7893d1ad171b3d6f94f41e8a1c7f78e2b403b1 · Zeichen 8573–8926 im Abschnitt
Nebenwirkungen · Ozempic
Ozempic 0.25 mg solution for injection in pre-filled pen Ozempic 0.5 mg solution for injection in pre-filled pen Ozempic 1 mg solution for injection in pre-filled pen Ozempic 2 mg solution for injection in pre-filled pen Ozempic 0.25 mg solution for injection in pre-filled syringe Ozempic 0.5 mg solution for injection in pre-filled syringe Ozempic 1 mg solution for injection in pre-filled syringe · Abschnitt 4.8 · PDF-Seite 10
HOS-135994 · Präparat HOS-097800
Diabetic retinopathy complications
A 2-year clinical trial investigated 3 297 patients with type 2 diabetes, with high cardiovascular risk,
long duration of diabetes and poorly controlled blood glucose. In this trial, adjudicated events of
diabetic retinopathy complications occurred in more patients treated with semaglutide (3%) compared
to placebo (1.8%). This was observed in insulin-treated patients with known diabetic retinopathy. The
treatment difference appeared early and persisted throughout the trial. Systematic evaluation of
diabetic retinopathy complication was only performed in the cardiovascular outcomes trial. In clinical
trials up to 1 year involving 4 807 patients with type 2 diabetes, adverse events related to diabetic
retinopathy were reported in similar proportions of subjects treated with semaglutide (1.7%) and
comparators (2.0%).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-25T12:02:00Z · SHA-256 57219aa6be0c50a4f2cc98001152ec6dcce36b4e4c6ae43650c37f58899b3d2c · Passage fd63ccbbb1fb15f42276329ed9e41b122056a281ac2b5c6673c7b0858b483a88 · Zeichen 8928–9788 im Abschnitt
Nebenwirkungen · Ozempic
Ozempic 0.25 mg solution for injection in pre-filled pen Ozempic 0.5 mg solution for injection in pre-filled pen Ozempic 1 mg solution for injection in pre-filled pen Ozempic 2 mg solution for injection in pre-filled pen Ozempic 0.25 mg solution for injection in pre-filled syringe Ozempic 0.5 mg solution for injection in pre-filled syringe Ozempic 1 mg solution for injection in pre-filled syringe · Abschnitt 4.8 · PDF-Seite 10
HOS-135995 · Präparat HOS-097800
Non-arteritic anterior ischaemic optic neuropathy (NAION)
Results from several large epidemiological studies suggest that exposure to semaglutide in adults with
type 2 diabetes is associated with an approximately two-fold increase in the relative risk of developing
NAION, corresponding to approximately one additional case per 10 000 person-years of treatment.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-25T12:02:00Z · SHA-256 57219aa6be0c50a4f2cc98001152ec6dcce36b4e4c6ae43650c37f58899b3d2c · Passage b0f198a6a61b63306bcd1009f6cb02c6a514eac1e02b0ef52a944d4ef127aebc · Zeichen 9790–10151 im Abschnitt
Nebenwirkungen · Ozempic
Ozempic 0.25 mg solution for injection in pre-filled pen Ozempic 0.5 mg solution for injection in pre-filled pen Ozempic 1 mg solution for injection in pre-filled pen Ozempic 2 mg solution for injection in pre-filled pen Ozempic 0.25 mg solution for injection in pre-filled syringe Ozempic 0.5 mg solution for injection in pre-filled syringe Ozempic 1 mg solution for injection in pre-filled syringe · Abschnitt 4.8 · PDF-Seite 10
HOS-135996 · Präparat HOS-097800
Discontinuation due to an adverse event
The incidence of discontinuation of treatment due to adverse events was 6.1% and 8.7% for patients
treated with semaglutide 0.5 mg and 1 mg, respectively, versus 1.5% for placebo. The most frequent
adverse events leading to discontinuation were gastrointestinal.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-25T12:02:00Z · SHA-256 57219aa6be0c50a4f2cc98001152ec6dcce36b4e4c6ae43650c37f58899b3d2c · Passage 2fdcb67a1bdfbdeb7164da46669609d3a43ce22d652a4578115c5c6733c0f06e · Zeichen 10153–10455 im Abschnitt
Nebenwirkungen · Ozempic
Ozempic 0.25 mg solution for injection in pre-filled pen Ozempic 0.5 mg solution for injection in pre-filled pen Ozempic 1 mg solution for injection in pre-filled pen Ozempic 2 mg solution for injection in pre-filled pen Ozempic 0.25 mg solution for injection in pre-filled syringe Ozempic 0.5 mg solution for injection in pre-filled syringe Ozempic 1 mg solution for injection in pre-filled syringe · Abschnitt 4.8 · PDF-Seite 10
HOS-135997 · Präparat HOS-097800
Injection site reactions
Injection site reactions (e.g. injection site rash, erythema) have been reported by 0.6% and 0.5% of
patients receiving semaglutide 0.5 mg and 1 mg, respectively. These reactions have usually been mild.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-25T12:02:00Z · SHA-256 57219aa6be0c50a4f2cc98001152ec6dcce36b4e4c6ae43650c37f58899b3d2c · Passage 97ec4c261c173f67ea8778fc60f101821a8a7b3516fef12edaeaaef4ad23311e · Zeichen 10457–10684 im Abschnitt
Nebenwirkungen · Ozempic
Ozempic 0.25 mg solution for injection in pre-filled pen Ozempic 0.5 mg solution for injection in pre-filled pen Ozempic 1 mg solution for injection in pre-filled pen Ozempic 2 mg solution for injection in pre-filled pen Ozempic 0.25 mg solution for injection in pre-filled syringe Ozempic 0.5 mg solution for injection in pre-filled syringe Ozempic 1 mg solution for injection in pre-filled syringe · Abschnitt 4.8 · PDF-Seite 10
HOS-135998 · Präparat HOS-097800
Immunogenicity
Consistent with the potentially immunogenic properties of medicinal products containing proteins or
peptides, patients may develop antibodies following treatment with semaglutide. The proportion of
patients tested positive for anti-semaglutide antibodies at any time point post-baseline was low (1−3%)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-25T12:02:00Z · SHA-256 57219aa6be0c50a4f2cc98001152ec6dcce36b4e4c6ae43650c37f58899b3d2c · Passage 831d30ae8df2de339b93cdd5f5a9224a140ce7afd1ed596e097a39a9a05b38c1 · Zeichen 10686–11002 im Abschnitt
Nebenwirkungen · Ozempic
Ozempic 0.25 mg solution for injection in pre-filled pen Ozempic 0.5 mg solution for injection in pre-filled pen Ozempic 1 mg solution for injection in pre-filled pen Ozempic 2 mg solution for injection in pre-filled pen Ozempic 0.25 mg solution for injection in pre-filled syringe Ozempic 0.5 mg solution for injection in pre-filled syringe Ozempic 1 mg solution for injection in pre-filled syringe · Abschnitt 4.8 · PDF-Seite 10–11
HOS-135999 · Präparat HOS-097800
10
and no patients had anti-semaglutide neutralising antibodies or anti-semaglutide antibodies with
endogenous GLP-1 neutralising effect at end-of-trial.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-25T12:02:00Z · SHA-256 57219aa6be0c50a4f2cc98001152ec6dcce36b4e4c6ae43650c37f58899b3d2c · Passage caddd72c17495ed4945ab3115245b3f7c5c62ea8899945d27971d4f56abf3c66 · Zeichen 11056–11210 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.